Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTP-miRNA106a
- Development stage
- Preclinical
- Lead developer
- Vivasc Therapeutics
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
CTP-miRNA106a is an investigational peptide-drug conjugate and RNA therapy being developed by Vivasc Therapeutics in collaboration with Georgetown University for the treatment of heart failure and cardiac hypertrophy. The drug consists of a Cardiac Targeting Peptide (CTP) reversibly linked via a disulfide bond to microRNA 106a (miRNA106a), designed to specifically deliver the miRNA cargo to cardiomyocytes. Once delivered to heart cells, miRNA106a downregulates the expression of key genes that contribute to cardiac hypertrophy and inflammation, including Calcium/calmodulin-dependent protein kinase type 2 delta (CaMKIIδ), Phospholipase C beta 1 (PLCβ1), and Histone deacetylase 4 (HDAC4). The drug is administered intravenously and has demonstrated the ability to reverse heart failure parameters in preclinical mouse models. It is currently undergoing in vivo optimization and IND-enabling studies supported by NIH Phase I STTR grants.
- Other names
- CTP-miR-106aCTP-miR106aCTP-miR 106aCTP-microRNA-106aCTP-microRNA106aCTP-microRNA 106a
02
Targets
PLCB1 (Phospholipase C beta 1)CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)HDAC4
Beyond the preview
Go deeper on CTP-miRNA106a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTP-miRNA106a.